- Home
- FIGS vs XERS Comparison
FIGS vs XERS Comparison
Compare FIGS & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- XERS
- Stock Information
- Founded
- FIGS 2013
- XERS 2005
- Country
- FIGS United States
- XERS United States
- Employees
- FIGS N/A
- XERS N/A
- Industry
- FIGS Apparel
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- XERS Health Care
- Exchange
- FIGS Nasdaq
- XERS Nasdaq
- Market Cap
- FIGS 1.3B
- XERS 1.3B
- IPO Year
- FIGS 2021
- XERS 2018
- Fundamental
- Price
- FIGS $8.10
- XERS $9.23
- Analyst Decision
- FIGS Hold
- XERS Strong Buy
- Analyst Count
- FIGS 5
- XERS 7
- Target Price
- FIGS $6.10
- XERS $8.00
- AVG Volume (30 Days)
- FIGS 1.5M
- XERS 2.2M
- Earning Date
- FIGS 11-06-2025
- XERS 11-06-2025
- Dividend Yield
- FIGS N/A
- XERS N/A
- EPS Growth
- FIGS N/A
- XERS N/A
- EPS
- FIGS 0.04
- XERS N/A
- Revenue
- FIGS $569,581,000.00
- XERS $246,025,000.00
- Revenue This Year
- FIGS $4.73
- XERS $43.89
- Revenue Next Year
- FIGS $3.67
- XERS $20.40
- P/E Ratio
- FIGS $186.55
- XERS N/A
- Revenue Growth
- FIGS 3.41
- XERS 35.62
- 52 Week Low
- FIGS $3.57
- XERS $2.82
- 52 Week High
- FIGS $8.50
- XERS $9.49
- Technical
- Relative Strength Index (RSI)
- FIGS 66.05
- XERS 64.63
- Support Level
- FIGS $7.94
- XERS $9.11
- Resistance Level
- FIGS $8.50
- XERS $9.49
- Average True Range (ATR)
- FIGS 0.27
- XERS 0.39
- MACD
- FIGS 0.07
- XERS 0.03
- Stochastic Oscillator
- FIGS 77.10
- XERS 85.09
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).